Hiroshima, Japan

Ryosaku Noumi

This inventor holds 1 USPTO granted patent. Top assignee: Ajinomoto Co., Ltd.. Active years: 1991.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1991

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Ryosaku Noumi

Introduction

Ryosaku Noumi is a notable inventor based in Hiroshima, Japan. He has made significant contributions to the field of antimicrobial agents, particularly through his work on antibiotic derivatives. His innovative approach has led to the development of compounds that exhibit high efficacy while maintaining lower toxicity levels.

Latest Patents

Noumi holds a patent for the Heptaene V-28-3 antibiotic derivative. This compound is recognized as an antimycotic agent with a high degree of antimicrobial activity towards Eumycetes. The Heptaene V-28-3 derivative is a methyl ester derivative that offers a promising alternative to existing antibiotics, showcasing its potential in medical applications.

Career Highlights

Throughout his career, Ryosaku Noumi has been associated with Ajinomoto Co., Ltd., a leading company in the food and biotechnology sectors. His work has not only advanced the understanding of antimicrobial agents but has also contributed to the development of safer and more effective treatments.

Collaborations

Noumi has collaborated with esteemed colleagues such as Hiroshiro Shibai and Koichi Ishii. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the field of antimicrobial research.

Conclusion

Ryosaku Noumi's contributions to the field of antibiotics, particularly through his patented Heptaene V-28-3 derivative, highlight his role as a significant inventor in the realm of antimicrobial agents. His work continues to influence the development of safer medical treatments.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…